샘플 요청 목록

 카트 문의
시장보고서
상품코드
1786453

세계의 DNA 복구 약물 시장

DNA Repair Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 217 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

DNA 복구 약물 세계 시장은 2030년까지 미국에서 195억 달러에 달할 전망

2024년에 83억 달러로 추정되는 DNA 복구 약물 세계 시장은 분석 기간인 2024-2030년에 CAGR 15.2%로 성장하여 2030년에는 195억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 표적요법은 CAGR 17.2%를 기록하며 분석 기간 종료까지 85억 달러에 달할 것으로 예상됩니다. 호르몬요법 분야의 성장률은 분석 기간 동안 CAGR 11.8%로 추정됩니다.

미국 시장은 22억 달러로 추정, 중국은 CAGR 14.2%로 성장 예측

미국의 DNA 복구 약물 시장은 2024년에 22억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 14.2%로 추정되며, 2030년까지 30억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 14.3%와 12.9%로 예측됩니다. 유럽에서는 독일이 CAGR 10.9%로 성장할 것으로 예측됩니다.

세계의 DNA 복구 약물 시장 - 주요 동향과 촉진요인 정리

DNA 복구 메커니즘을 표적으로 삼는 것이 암 치료의 패러다임을 재정의할 수 있을까?

DNA 복구 메커니즘에 대한 연구는 치료적으로 이용 가능한 암세포의 취약성을 밝혀냄으로써 종양학에 혁명을 일으켰습니다. 유전체 무결성 유지에 관여하는 특정 효소나 경로를 표적으로 삼는 DNA 복구 약물은 이러한 변화의 최전선에 있습니다. 암세포는 주요 복구 경로의 결함으로 인해 대체 DNA 복구 메커니즘에 크게 의존하는 경우가 많습니다. 합성 치사로 알려진 이 개념은 PARP(폴리 ADP 리보스 중합효소) 억제제와 같이 FDA 승인을 받은 여러 약물의 기초가 되었으며, BRCA 돌연변이 난소암, 유방암, 췌장암, 전립선암 치료에 탁월한 효능을 보이고 있습니다. DNA 복구 억제제의 유망성은 정상 세포를 보존하면서 종양 세포를 선택적으로 사멸시키는 능력에 있으며, 화학요법에서 흔히 발생하는 표적 외 독성을 감소시키는데 있습니다. PARP 외에도 ATM, ATR, DNA-PK, CHK1/2, POLQ 등 DNA 손상에 대한 세포 반응에 중요한 역할을 하는 다양한 표적들을 적극적으로 탐색하고 있습니다. 이러한 새로운 치료법은 면역요법, 방사선요법, 전통적 화학요법과 함께 단독요법 및 병용요법으로 평가받고 있습니다. DNA 복구를 표적으로 하는 치료법의 정확성과 개별화로 인해 개인의 유전체 프로파일에 맞춘 보다 효과적인 치료 전략이 가능해졌습니다. 따라서 바이오마커 중심의 약물 개발은 이 분야에서 핵심적인 역할을 하고 있으며, 동반진단이 가장 효과적일 것으로 기대되는 환자를 식별하는 데 활용되고 있습니다. DNA 손상 반응(DDR) 네트워크에 대한 이해가 깊어짐에 따라 DNA 복구 약물은 암 치료 방법을 재정의하고 있습니다. 즉, 만능 모델에서 고도로 표적화된 기전 특이적 접근법으로 전환하여 암학의 새로운 시대를 맞이하고 있습니다.

유전체학 및 바이오마커 과학의 발전은 의약품 개발을 어떻게 촉진하고 있는가?

유전체학, 시퀀싱, 분자진단의 기술적 발전은 종양의 DNA 복구 결손을 정확하게 식별할 수 있게함으로써 DNA 복구 약물의 개발과 임상 적용을 촉진하고 있습니다. BRCA1/2, ATM, PALB2, 기타 상동 재조합 복구(HRR) 및 불일치 복구(MMR) 경로의 구성요소와 같은 유전자의 돌연변이를 검출하기 위해 현재 하이스루풋 시퀀싱 및 차세대 시퀀싱(NGS) 플랫폼이 널리 사용되고 있습니다. 이러한 인사이트를 통해 임상의와 연구자들은 유전적 구성에 따라 환자를 계층화하여 치료 반응을 보다 정확하게 예측할 수 있습니다. 또한, "BRCAness", 상동결합결손(HRD) 점수 등 새로운 유전체 시그니처의 발견으로 DNA 복구 약물의 적격성 기준은 생식세포 계열의 BRCA 유전자 변이에만 국한되지 않고 확대되고 있습니다. 순환 종양 DNA(ctDNA)를 검출하는 액체 생검도 실시간으로 치료 반응성과 저항성을 모니터링하는 최소침습적 도구로 각광받고 있습니다. 바이오마커에 기반한 의약품 개발은 제약회사들에게 중요한 전략이 되고 있으며, 풍부한 환자군과 더 높은 성공 확률을 가진 보다 스마트한 임상시험을 설계하는 데 도움을 주고 있습니다. 또한, CRISPR-Cas9 유전자 편집은 특정 DNA 복구 유전자의 역할과 암 진행에 대한 기여도를 더 잘 이해하기 위해 전임상 모델에서 사용되어 새로운 치료 표적 발굴의 길을 열어주고 있습니다. 또한, 인실리코 모델링과 AI 기반 신약개발 플랫폼은 더 높은 선택성과 효능을 가진 저분자 억제제 발굴을 가속화하고 있습니다. 이러한 기술적 시너지 효과는 약물 설계를 정교화할 뿐만 아니라 보다 견고한 임상 파이프라인을 가능하게 하고, 분자 수준에서 정의된 종양 아형에 맞는 차세대 DNA 복구 약물을 위한 무대를 마련하고 있습니다.

암 이외의 치료 영역 확대로 시장 가능성 확대?

DNA 복구 약물의 주요 용도는 여전히 암 치료이지만, 이들 약물의 잠재적 치료 범위는 암 이외의 다양한 질환으로 확대되고 있어 시장의 잠재력을 크게 확장하고 있습니다. DNA 복구 메커니즘은 노화, 염증, 신경변성 등 유전체 불안정성이 질병의 발병과 진행에 관여하는 영역에서 중요한 역할을 합니다. 알츠하이머병, 파킨슨병, 헌팅턴병과 같은 신경퇴행성 질환에서 DNA 손상 반응 경로의 결함이 신경세포 사멸과 인지기능 저하의 원인이라는 증거가 점점 더 많이 제시되고 있습니다. 연구진은 DNA 복구 효소를 조절함으로써 질병의 진행을 늦추거나 신경 보호를 강화할 수 있는지 여부를 조사하고 있습니다. 마찬가지로, 자가면역질환이나 운동실조증성 척수확장증, 판코니 빈혈과 같은 희귀한 유전성 질환도 DNA 복구효소 결핍으로 특징지어지는데, DNA 복구효소를 조절하는 새로운 치료법으로 주목받고 있습니다. 또한, 방사선 노출은 암 치료로 인한 것이든 환경적인 것이든 DNA 손상을 유발하기 때문에 DNA 복구 촉진제를 개발함으로써 건강한 조직을 보호하고 장기적인 영향을 완화할 수 있습니다. 제약사들은 암 영역에서는 억제제로, 다른 질환에서는 보호제로, 적용 방법에 따라 양면으로 사용할 수 있는 분자를 모색하고 있습니다. 이러한 치료적 유연성은 DNA 복구 약물 후보물질의 상업적 매력을 높이고, 더 광범위한 R&D 투자를 촉진하고 있습니다. 특히 건강 수명의 핵심인 유전체 유지에 초점을 맞춘 노화 연구의 부상은 DNA 복구 경로를 잠재적인 개입 포인트로 주목하고 있습니다. 과학계가 DNA 손상, 만성질환, 세포 노화의 상호 연관성을 계속 탐구하는 가운데, DNA 복구 약물의 관련성은 암을 넘어 훨씬 더 확장되어 가치 있는 임상적 응용을 실현하고 있습니다.

DNA 복구 약물 시장의 성장을 촉진하는 요인은 무엇인가?

DNA 복구 약물 시장의 성장은 과학적 혁신, 정밀 의료, 진화하는 치료 전략에 뿌리를 둔 몇 가지 요인에 의해 주도되고 있습니다. 주요 촉진요인은 전 세계 암 유병률의 증가와 보다 표적화되고 독성이 낮은 치료법에 대한 수요 증가입니다. DNA 복구 억제제, 특히 PARP 억제제는 BRCA 돌연변이 종양과 상동결합결손 종양의 생존 예후를 개선하는 데 이미 성공을 거두어 채택률 증가와 새로운 적응증 획득으로 이어지고 있습니다. 개인맞춤의료의 추진도 중요한 요인 중 하나이며, 임상의들은 DNA 복구 유전자에 돌연변이가 있어 이러한 치료가 효과가 있는 환자를 식별하기 위해 분자 프로파일링을 활용하고 있습니다. 시퀀싱 기술과 동반진단 약물의 발전으로 이러한 정밀 타겟팅이 더욱 현실적이고 비용 효율적일 수 있게 되었습니다. 또한, 제약 업계에서 병용요법에 대한 강조가 확대되고 있으며, DNA 복구 약물은 면역관문억제제, 화학요법, 방사선 요법과 함께 효능을 높이고 내성을 극복하기 위해 사용되고 있어 시장 성장에 중요한 역할을 하고 있습니다. ATR, ATM, DNA-PK 및 기타 DDR 표적에 대한 억제제를 탐색하는 임상시험의 수가 증가하고 있는 것은 개발 파이프라인이 견고하고 성장하고 있음을 반영합니다. 또한, 생명공학 스타트업과 대형 제약사와의 전략적 제휴를 통해 초기 단계의 연구에서 실행 가능한 치료 후보물질로의 전환이 가속화되고 있습니다. 규제 당국도 패스트트랙 지정, 혁신 치료제 승인, 승인 의약품의 적응증 확대 등을 통해 혁신을 지원하고 있습니다. 시판 후 임상시험에서 얻은 실제 증거의 출현은 이러한 치료법의 장기적인 유용성을 검증하고, 상환 결정을 유도하는 데 도움이 되고 있습니다. 마지막으로, 종양학 및 노화 연구에 대한 공공 및 민간 투자는 DNA 복구 생물학에 대한 지속적인 연구를 위한 비옥한 환경을 조성하여 시장의 모멘텀을 더욱 가속화하고 있습니다. 이러한 상호 연관된 추진력으로 인해 DNA 복구 약물은 종양학 및 기타 분야에서 차세대 치료 전략의 초석으로 자리매김하고 있습니다.

부문

유방암 치료제(표적요법, 호르몬요법, 화학요법, 면역요법), 유방암 치료제 암 유형(호르몬 수용체 유형, HER2+유형), 유방암 치료제 유통 채널(병원 약국, 소매 약국, 기타 유통 채널)

조사 대상 기업 사례

  • AbbVie Inc.
  • Agios Pharmaceuticals, Inc.
  • Allarity Therapeutics A/S
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Breakpoint Therapeutics
  • Bristol-Myers Squibb Company
  • Clovis Oncology
  • Eli Lilly and Company
  • FoRx Therapeutics
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Lantern Pharma Inc.
  • Luciole Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSM 25.08.14

Global DNA Repair Drugs Market to Reach US$19.5 Billion by 2030

The global market for DNA Repair Drugs estimated at US$8.3 Billion in the year 2024, is expected to reach US$19.5 Billion by 2030, growing at a CAGR of 15.2% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 17.2% CAGR and reach US$8.5 Billion by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at 11.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 14.2% CAGR

The DNA Repair Drugs market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Billion by the year 2030 trailing a CAGR of 14.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.3% and 12.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.9% CAGR.

Global DNA Repair Drugs Market - Key Trends & Drivers Summarized

Is Targeting DNA Repair Mechanisms Redefining Cancer Therapy Paradigms?

The study of DNA repair mechanisms has revolutionized oncology by uncovering vulnerabilities in cancer cells that can be therapeutically exploited. DNA repair drugs, which target specific enzymes and pathways involved in maintaining genomic integrity, are at the forefront of this transformation. Cancer cells often rely heavily on alternative DNA repair mechanisms due to defects in their primary repair pathways-making them uniquely sensitive to targeted inhibition. This concept, known as synthetic lethality, is the foundation for several FDA-approved drugs, such as PARP (poly ADP-ribose polymerase) inhibitors, which have demonstrated remarkable efficacy in treating BRCA-mutated ovarian, breast, pancreatic, and prostate cancers. The promise of DNA repair inhibitors lies in their ability to selectively kill tumor cells while sparing normal cells, reducing off-target toxicity commonly associated with chemotherapy. Beyond PARP, the industry is actively exploring a range of targets including ATM, ATR, DNA-PK, CHK1/2, and POLQ, each playing vital roles in the cellular response to DNA damage. These emerging therapies are being evaluated as both monotherapies and combination regimens alongside immunotherapy, radiation, and traditional chemotherapy. The precision and personalization of DNA repair-targeted therapies are enabling more effective treatment strategies tailored to individual genomic profiles. Biomarker-driven drug development is thus central to this field, as companion diagnostics are used to identify patients most likely to benefit. As understanding of the DNA damage response (DDR) network deepens, DNA repair drugs are redefining the way cancers are treated-shifting from a one-size-fits-all model to a highly targeted, mechanism-specific approach that marks a new era in oncology.

How Are Advances in Genomics and Biomarker Science Powering Drug Development?

Technological advancements in genomics, sequencing, and molecular diagnostics are driving the development and clinical application of DNA repair drugs by enabling precise identification of DNA repair deficiencies in tumors. High-throughput sequencing and next-generation sequencing (NGS) platforms are now widely used to detect mutations in genes like BRCA1/2, ATM, PALB2, and other components of the homologous recombination repair (HRR) and mismatch repair (MMR) pathways. These insights allow clinicians and researchers to stratify patients based on their genetic makeup and predict treatment response more accurately. Furthermore, the discovery of novel genomic signatures such as "BRCAness" or homologous recombination deficiency (HRD) scores is expanding the eligibility criteria for DNA repair drugs beyond just germline BRCA mutations. Liquid biopsies, which detect circulating tumor DNA (ctDNA), are also gaining traction as minimally invasive tools to monitor treatment response and resistance in real time. Biomarker-guided drug development has become a key strategy for pharmaceutical companies, helping them design smarter clinical trials with enriched patient populations and higher success probabilities. Moreover, CRISPR-Cas9 gene editing is being used in preclinical models to better understand the role of specific DNA repair genes and their contribution to cancer progression, paving the way for the identification of new therapeutic targets. In silico modeling and AI-driven drug discovery platforms are also accelerating the identification of small-molecule inhibitors with higher selectivity and potency. These technological synergies are not only refining drug design but also enabling more robust clinical pipelines, setting the stage for a new generation of DNA repair drugs tailored to molecularly defined tumor subtypes.

Is the Expanding Therapeutic Scope Beyond Cancer Broadening Market Potential?

While oncology remains the primary application for DNA repair drugs, the potential therapeutic scope of these agents is expanding to include a variety of non-oncological conditions, which is significantly broadening the market’s potential. DNA repair mechanisms play a crucial role in aging, inflammation, and neurodegeneration-areas where genomic instability contributes to disease onset and progression. In neurodegenerative disorders like Alzheimer’s, Parkinson’s, and Huntington’s disease, growing evidence suggests that defects in DNA damage response pathways may contribute to neuronal death and cognitive decline. Researchers are investigating whether modulating DNA repair enzymes could slow disease progression or enhance neuroprotection. Similarly, autoimmune diseases and rare genetic disorders such as ataxia-telangiectasia and Fanconi anemia-characterized by inherent DNA repair deficiencies-are emerging as new therapeutic frontiers for DNA repair modulation. Moreover, radiation exposure, whether from cancer therapy or environmental sources, induces DNA damage, and DNA repair enhancers could be developed to protect healthy tissues or mitigate long-term effects. Pharmaceutical companies are exploring dual-use molecules that serve both as inhibitors in oncology and as protectants in other diseases, depending on how they are applied. This therapeutic flexibility increases the commercial attractiveness of DNA repair drug candidates, encouraging broader R&D investment. The rise of aging research, particularly focused on genome maintenance as a pillar of healthy longevity, is drawing attention to DNA repair pathways as potential intervention points. As the scientific community continues to explore the interconnectedness of DNA damage, chronic disease, and cellular aging, the relevance of DNA repair drugs is expanding far beyond cancer, unlocking a multitude of high-value clinical applications.

What Are the Core Drivers Fueling Growth in the DNA Repair Drugs Market?

The growth in the DNA repair drugs market is driven by several factors deeply rooted in scientific innovation, precision medicine, and evolving therapeutic strategies. A major driver is the growing prevalence of cancer worldwide, which is increasing demand for more targeted and less toxic therapies. DNA repair inhibitors, particularly PARP inhibitors, have already shown success in improving survival outcomes in BRCA-mutated and homologous recombination-deficient tumors, leading to rising adoption and new indications. The push toward personalized medicine is another key factor-clinicians are increasingly using molecular profiling to identify patients with DNA repair gene mutations who can benefit from these therapies. Advances in sequencing technologies and companion diagnostics are making such precision targeting more feasible and cost-effective. Additionally, the pharmaceutical industry’s expanding focus on combination therapies is playing a critical role in market growth, with DNA repair drugs being used alongside immune checkpoint inhibitors, chemotherapy, and radiation to enhance efficacy and overcome resistance. The increasing number of clinical trials exploring inhibitors of ATR, ATM, DNA-PK, and other DDR targets reflects a robust and growing development pipeline. Moreover, strategic collaborations between biotech startups and large pharmaceutical companies are accelerating the translation of early-stage research into viable therapeutic candidates. Regulatory bodies are also supporting innovation through fast-track designations, breakthrough therapy approvals, and expanded label indications for approved drugs. The emergence of real-world evidence from post-marketing studies is helping validate the long-term benefits of these treatments and guiding reimbursement decisions. Finally, public and private investments in oncology and aging research are creating a fertile environment for continued exploration of DNA repair biology, further propelling market momentum. These interconnected drivers are collectively positioning DNA repair drugs as a cornerstone of next-generation therapeutic strategies across oncology and beyond.

SCOPE OF STUDY:

The report analyzes the DNA Repair Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Breast Cancer Drugs Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy, Immunotherapy Therapy); Breast Cancer Drugs Cancer Type (Hormone Receptor Type, HER2+ Type); Breast Cancer Drugs Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Agios Pharmaceuticals, Inc.
  • Allarity Therapeutics A/S
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Breakpoint Therapeutics
  • Bristol-Myers Squibb Company
  • Clovis Oncology
  • Eli Lilly and Company
  • FoRx Therapeutics
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Lantern Pharma Inc.
  • Luciole Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • DNA Repair Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Cancer Genomics Throw the Spotlight on DNA Repair Pathways as Therapeutic Targets
    • Success of PARP Inhibitors Propels Growth and Validates the DNA Repair Drug Development Model
    • Rising Prevalence of BRCA and HRD-Related Cancers Strengthens Business Case for Synthetic Lethality-Based Therapies
    • Expansion of Companion Diagnostics Accelerates Adoption of Biomarker-Guided DNA Repair Treatments
    • Integration of DNA Repair Drugs into Combination Therapy Regimens Spurs Broader Oncology Use Cases
    • Growing Focus on Tumor-Specific Vulnerabilities Drives Development of Novel DDR (DNA Damage Response) Inhibitors
    • Emerging Targets Beyond PARP, Including ATR, ATM, DNA-PK, and POLQ, Expand Addressable Therapeutic Pipeline
    • Increased Investment in Precision Oncology Programs Fuels R&D Activity in DNA Repair Modulators
    • Use of CRISPR and Functional Genomics in Drug Discovery Enhances Target Validation and Pipeline Innovation
    • Real-World Evidence and Post-Market Data Strengthen Confidence in Long-Term Clinical Benefits
    • Growing Applications in Prostate, Pancreatic, and Ovarian Cancers Drive Indication Expansion
    • Potential Utility in Non-Oncological Conditions Opens New Growth Frontiers for DNA Repair Modulation
    • Global Rise in Personalized Medicine Initiatives Generates Sustained Demand for Genomic Repair Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World DNA Repair Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for DNA Repair Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for DNA Repair Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for DNA Repair Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Chemotherapy Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunotherapy Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Immunotherapy Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hormone Receptor Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hormone Receptor Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hormone Receptor Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for HER2+ Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for HER2+ Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for HER2+ Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for DNA Repair Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for DNA Repair Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • DNA Repair Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for DNA Repair Drugs by Breast Cancer Drugs Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy Therapy and Immunotherapy Therapy for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Hormone Receptor Type and HER2+ Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Cancer Type - Percentage Breakdown of Value Sales for Hormone Receptor Type and HER2+ Type for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of World 15-Year Perspective for DNA Repair Drugs by Breast Cancer Drugs Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제